ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $548.69 ($545.93–$553.24, $5.21M total) across 8 trades on 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price range ($545.9257–$553.2448), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Insider selling can be a sentiment input, but the pre-arranged 10b5-1 structure makes this more of a routine flow than a new fundamental catalyst.
What to watch
Traders should check for other contemporaneous insider transactions or company news; a single Form 4 sale often has limited predictive value.
Background
The article is a SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics insider sale: CEO/Chair Martine Rothblatt sold 9,500 shares for ~$5.21M under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless accompanied by other new company-specific news.
The filing is a Form 4 detailing an open-market sale with an explicitly stated pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.
Market effects
Minimal; insider sale does not indicate sector-wide regulatory/clinical/product changes.
None indicated; event is company-specific and not macro-linked.
None indicated; no international transaction or cross-border catalyst described.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Company whose shares were sold by an insider under a Form 4 disclosure.
- insiderROTHBLATT MARTINE A
Chairperson & CEO who executed the open-market sale of 9,500 shares.
